Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Non-Nucleoside Reverse Transcriptase Inhibitors
Etravirine (Intelence, ETR)
Last Updated: December 7, 2018; Last Reviewed: December 7, 2018
Excerpt from Table 10
|Formulation||Dosing Recommendationsa||Use in Pregnancy|
||Standard Adult Dose:
PK in Pregnancy:
Dosing in Pregnancy:
|Variable placental transfer, usually in the moderate to high categories, ranging from 0.19–4.25 (data from 19 mother-infant pairs).b
Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.
a Individual ARV drug dosages may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 8).
b Placental transfer categories are determined by mean or median cord blood/maternal delivery plasma drug ratio:
Key to Acronyms: ARV = antiretroviral; ETR= etravirine; PK = pharmacokinetic
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive